Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback